Scientists at the University of Cambridge have reported a breakthrough in the quest to develop vaccines that can protect against entire families of viruses, including future threats that have yet to emerge.
Researchers from the university and biotechnology company DIOSynVax recently completed the first human trial of an artificial intelligence-designed “universal” coronavirus vaccine. The early-stage study involved 39 healthy volunteers and showed the vaccine caused no significant side effects.
Unlike conventional vaccines that target specific virus strains, the new vaccine uses AI technology to identify common genetic features shared across multiple coronaviruses. Scientists then combine those features into a single vaccine component designed to trigger broader immune protection.
The researchers designed the vaccine to protect against Sarbeco coronaviruses, a group that includes SARS-CoV-2, the virus responsible for COVID-19, as well as SARS and related bat viruses that could infect humans in the future.
Professor Jonathan Heeney, who led the research, said the technology could transform vaccine development by providing protection against future variants before they emerge.
Early trial results showed that volunteers developed immune responses against known coronaviruses and related animal viruses that have not yet caused human outbreaks.
Professor Saul Faust, chief investigator of the trial, said the vaccine could help prevent future pandemics if researchers successfully advance it through larger clinical trials.
The team plans to launch a Phase 2 study to evaluate the vaccine’s effectiveness in a broader population and determine the strength of the protection it provides.
Scientists believe the technology could eventually support the development of universal vaccines against other virus families, including influenza and Ebola, reducing the need for constant vaccine updates and strengthening global pandemic preparedness.
